These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10720684)

  • 1. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines.
    van Os N; Niessen LW; Bilo HJ; Casparie AF; van Hout BA
    Health Policy; 2000 Apr; 51(3):135-47. PubMed ID: 10720684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis.
    Ortegon MM; Redekop WK; Niessen LW
    Diabetes Care; 2004 Apr; 27(4):901-7. PubMed ID: 15047646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
    Critselis E; Vlahou A; Stel VS; Morton RL
    Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes.
    Schouten LM; Niessen LW; van de Pas JW; Grol RP; Hulscher ME
    Med Care; 2010 Oct; 48(10):884-91. PubMed ID: 20808258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.
    Adarkwah CC; Gandjour A; Akkerman M; Evers SM
    PLoS One; 2011; 6(10):e26139. PubMed ID: 22022539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness and cost-utility of at-home infrared temperature monitoring in reducing the incidence of foot ulcer recurrence in patients with diabetes (DIATEMP): study protocol for a randomized controlled trial.
    Aan de Stegge WB; Mejaiti N; van Netten JJ; Dijkgraaf MGW; van Baal JG; Busch-Westbroek TE; Bus SA
    Trials; 2018 Sep; 19(1):520. PubMed ID: 30249296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results?
    Szmurło D; Schubert A; Kostrzewska K; Ryś P; Skrzekowska-Baran I
    Pol Arch Med Wewn; 2011 Oct; 121(10):345-50. PubMed ID: 22045095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus.
    Wallner K; Shapiro AM; Senior PA; McCabe C
    BMC Endocr Disord; 2016 Apr; 16():17. PubMed ID: 27061400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.